Renal cancer subtypes: Should we be lumping or splitting for therapeutic decision making?
出版年份 2016 全文链接
标题
Renal cancer subtypes: Should we be lumping or splitting for therapeutic decision making?
作者
关键词
-
出版物
CANCER
Volume 123, Issue 2, Pages 200-209
出版商
Wiley
发表日期
2016-11-17
DOI
10.1002/cncr.30314
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma
- (2016) A. Ari Hakimi et al. CANCER CELL
- Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression
- (2016) S. A. Brooks et al. CLINICAL CANCER RESEARCH
- Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations
- (2016) Gabriel G. Malouf et al. EUROPEAN UROLOGY
- The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours
- (2016) Holger Moch et al. EUROPEAN UROLOGY
- Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression
- (2016) Richard W. Joseph et al. JOURNAL OF UROLOGY
- Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
- (2016) NEW ENGLAND JOURNAL OF MEDICINE
- Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities
- (2016) Scott M. Haake et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†
- (2015) A. Ravaud et al. ANNALS OF ONCOLOGY
- Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma
- (2015) M. Dror Michaelson et al. CANCER
- Survival Prediction of Clear Cell Renal Cell Carcinoma Based on Gene Expression Similarity to the Proximal Tubule of the Nephron
- (2015) Florian Büttner et al. EUROPEAN UROLOGY
- Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity
- (2015) Brian Shuch et al. EUROPEAN UROLOGY
- Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine
- (2015) Amanda J. Redig et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 expression in nonclear-cell renal cell carcinoma
- (2014) T. K. Choueiri et al. ANNALS OF ONCOLOGY
- The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma
- (2014) Caleb F. Davis et al. CANCER CELL
- Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
- (2014) M. H. Voss et al. CLINICAL CANCER RESEARCH
- The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma
- (2014) David F. McDermott et al. CLINICAL CANCER RESEARCH
- Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial
- (2014) T. K. Choueiri et al. CLINICAL CANCER RESEARCH
- ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma
- (2014) Samira A. Brooks et al. EUROPEAN UROLOGY
- Molecular Pathways: Fumarate Hydratase-Deficient Kidney Cancer--Targeting the Warburg Effect in Cancer
- (2013) W. M. Linehan et al. CLINICAL CANCER RESEARCH
- Collecting Duct Carcinomas Represent a Unique Tumor Entity Based on Genetic Alterations
- (2013) Frank Becker et al. PLoS One
- A Phase 2 Trial of Sunitinib in Patients with Advanced Non–clear Cell Renal Cell Carcinoma
- (2012) Nizar M. Tannir et al. EUROPEAN UROLOGY
- SMARCB1/INI1 inactivation in renal medullary carcinoma
- (2012) Julien Calderaro et al. HISTOPATHOLOGY
- Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
- (2012) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- The VHL/HIF axis in clear cell renal carcinoma
- (2012) Chuan Shen et al. SEMINARS IN CANCER BIOLOGY
- Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma
- (2010) Toni K. Choueiri et al. CANCER
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma
- (2008) John D. Gordan et al. CANCER CELL
- Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors
- (2008) M. L. Nickerson et al. CLINICAL CANCER RESEARCH
- Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma
- (2007) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started